Group 1 - Leshan Electric achieved operating revenue of 1.623 billion yuan, a year-on-year increase of 1.94%, and a net profit of 7.9031 million yuan, a year-on-year decrease of 14.55% [1] - Zhimingda reported operating revenue of 295 million yuan, a year-on-year increase of 84.83%, and a net profit of 38.3 million yuan, a year-on-year increase of 2147.93% [2] - Dahu Co. reported operating revenue of 426 million yuan, a year-on-year decrease of 14.40%, and a net loss of 2.5716 million yuan, an improvement from a loss of 13.7824 million yuan in the same period last year [3] - Yubang Electric expects a net profit of 21.2 million to 25 million yuan, a year-on-year decrease of 35.47% to 45.28% [4] - Zhejiang Securities achieved operating revenue of 6.512 billion yuan, a year-on-year decrease of 18.60%, and a net profit of 1.149 billion yuan, a year-on-year increase of 46.54% [5] - Huashu Media reported operating revenue of 4.435 billion yuan, a year-on-year increase of 2.07%, and a net profit of 254 million yuan, a year-on-year increase of 4.63% [7] Group 2 - Sinopec reported oil and gas equivalent production of 262.81 million barrels, a year-on-year increase of 2%, and crude oil processing volume of 119.97 million tons, a year-on-year decrease of 5.3% [8] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS8179, aimed at reducing brain edema after stroke [8] - Hengrui Medicine's subsidiary also received approval for clinical trials of HRS-1893, intended for treating heart failure with preserved ejection fraction [8] - Wanfu Co. announced a plan to reduce its stake by up to 2% through block trading [10] - Biological Co. received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inaccuracies in financial reporting [11] - Zhujiang Co. reported a signed construction area of 47.1432 million square meters across 396 projects [13] Group 3 - Watson Bio received a patent for a peptide delivery system for RNA drugs [15] - Sanwei Chemical signed 31 new contracts worth 335 million yuan in the second quarter [17] - Shenzhou Cell's SCT640C injection received approval for clinical trials for rheumatoid arthritis [18] - Xinjiang Jiaojian reported new contracts worth 1.434 billion yuan in the second quarter [19] - Lais Information plans to use 550 million yuan of idle funds for cash management [21] - Zhongqi New Materials signed a mining rights transfer contract, increasing production capacity [22] Group 4 - Hengtong Optic-Electric won multiple marine energy projects worth 1.509 billion yuan [24] - China State Construction signed new contracts totaling 2.501 trillion yuan in the first half of the year [26] - David Medical's ventilator product registration application has been accepted [28] - Tianhai Defense's subsidiary signed a construction contract worth 16.224 million yuan [29] - Nantian Information plans to sign a procurement framework contract worth 58.27 million yuan with its controlling shareholder [31] - Baida Group announced a plan to reduce its stake by up to 3% [32] Group 5 - Jinli Permanent Magnet plans to issue $117.5 million in convertible bonds [34] - Haizheng Pharmaceutical's fumarate bedaquiline raw material drug application has been approved [36] - Huatai passed the advanced intelligent factory re-evaluation in Anhui Province [37] - Everbright Bank's shareholder increased its stake from 7.08% to 8% [40] - Supor reported total operating revenue of 11.478 billion yuan, a year-on-year increase of 4.68%, and a net profit of 940 million yuan, a year-on-year decrease of 0.07% [41] - Qianjin Pharmaceutical's subsidiaries received registration certificates for two drugs [42]

Group 1 - Titan Technology plans to acquire 100% of Apollo Scientific Ltd. for approximately 55.85 million yuan, enhancing its global supply chain and competitiveness in the reagent field [1] - Qianjin Pharmaceutical has received registration certificates for two drugs, enriching its product line and strengthening its position in the treatment of vitamin B12 deficiency and heart failure [2] - Meizhong Jiahe intends to raise approximately 270 million HKD through a share placement, focusing on hospital construction, medical AI, and operational funding [3] Group 2 - ST Weiming has successfully recovered 100% equity of Xiamen Weiming, resolving long-standing equity disputes and stabilizing corporate governance [4] - Guangji Pharmaceutical has been fined 1.5 million yuan for information disclosure violations, highlighting governance issues and the need for compliance to restore investor confidence [5]

药品名称：腺苷钴胺胶囊 剂型：胶囊剂 证券代码：600479 证券简称：千金药业 公告编号：2025-039 株洲千金药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，株洲千金药业股份有限公司（以下简称"公司"）下属子公司湖南千 金湘江药业股份有限公司（以下简称"千金湘江药业"）收到国家药品监督管理 局核准签发的腺苷钴胺胶囊（0.5mg）《药品注册证书》（证书编号：2025S02155）， 公司下属子公司湖南千金协力药业有限公司（以下简称"千金协力药业"）收到 国家药品监督管理局核准签发的沙库巴曲缬沙坦钠片（100mg）《药品注册证书》 （证书编号：2025S02192）。现将相关情况公告如下： 一、药品基本信息 （一）腺苷钴胺胶囊 规格：0.5mg 注册分类：化学药品 3 类 药品批准文号：国药准字 H20254834 药品上市许可持有人：湖南千金湘江药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册， ...

当日关注点 截至2025年7月18日收盘，千金药业(600479)报收于10.93元，上涨0.18%，换手率1.83%，成交量7.67万 手，成交额8358.04万元。 交易信息汇总 7月18日，千金药业的资金流向情况如下：主力资金净流出92.58万元，占总成交额1.11%；游资资金净 流出386.41万元，占总成交额4.62%；散户资金净流入478.99万元，占总成交额5.73%。 公司公告汇总 千金药业发布了2024年度权益分派实施公告，主要内容如下：- 证券代码：600479，证券简称：千金药 业，公告编号：2025-038。- A股每股现金红利0.36元。- 股权登记日为2025年7月24日，除权（息）日及 现金红利发放日均为2025年7月25日。- 分配方案为每股派发现金红利0.36元（含税），共计派发现金红 利150,662,562.12元。- 自然人股东和证券投资基金根据持股期限不同，实际税负和发放现金红利金额有 所不同。- QFII股东由公司按10%的税率代扣代缴企业所得税，税后每股实际派发现金红利为人民币 0.324元。- 其他机构投资者和法人股东实际每股派发现金红利为人民币0.36元。- ...

株洲千金药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.36元 一、 通过分配方案的股东大会届次和日期 证券代码：600479 证券简称：千金药业 公告编号：2025-038 本次利润分配方案经公司2025 年 5 月 29 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本418,507,117股为基数，每股派发现金红利0.36 元（含税） ，共计派发现金红利150,662,562.12元。 三、 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/24 | － | 2025/7/25 | 2025/7/25 | | 四 ...

2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 证券代码：600479 证券简称：千金药业 公告编号：2025-038 株洲千金药业股份有限公司 A 股每股现金红利0.36元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/24 | － | 2025/7/25 | 2025/7/25 | 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本418,507,117股为基数，每股派发现金红利0.36 元（含税），共计派发现金红利150,662,562.12元。 1. 发放年度：2024年年度 2. 分派对象： 三、 相关日期 差异化分红送转： 否 一、 通过分配方案的股东 ...

株洲千金药业股份有限公司 关于限制性股票回购注销实施公告 证券代码：600479 证券简称：千金药业 公告编号：2025-037 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：株洲千金药业股份有限公司（以下简称"公 司"）2021 年限制性股票激励计划第二个及第三个解除限售期解除限 售条件未成就，公司拟对所涉激励对象已获授但尚未解除限售的 5,490,000 股限制性股票予以回购注销。 本次回购注销股份的有关情况 | 回购股份数（股） | 注销股份数（股） | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | | 5,490,000 | 5,490,000 | 2025 | 年 7 | 月 | 10 日 | 一、本次限制性股票回购注销的决策与信息披露 1.2025 年 4 月 25 日，公司召开第十一届董事会第十二次会议和 第十一届监事会第十一次会议，审议通过《关于公司 2021 年限制性 股票激励计划第二个及第三个解除限售期解除限售条件未成就 ...

湖南启元律师事务所 关于株洲千金药业股份有限公司 2021年限制性股票激励计划 致：株洲千金药业股份有限公司 湖南启元律师事务所（以下简称"本所"）接受株洲千金药业股份有限公司 （以下简称"公司"或"千金药业"）委托，担任千金药业 2021 年限制性股票 激励计划（以下简称"本次激励计划"）的专项法律顾问。 部分限制性股票回购注销实施情况的 法律意见书 湖南启元律师事务所 关于株洲千金药业股份有限公司 2021 年限制性股票激励计划 部分限制性股票回购注销实施情况的 法律意见书 本所根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市 公司股权激励管理办法》（以下简称"《管理办法》"）、《国有控股上市公司 (境内)实施股权激励试行办法》、《关于规范国有控股上市公司实施股权激励制 度有关问题的通知》等法律、法规和规范性文件以及《株洲千金药业股份有限公 司章程》，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，现就公司 2021 年限制性股票激励计划部分限制性股票回购注销实施（以下简称"本次回 购注销"）相关事宜，出具本法律意见书。 为出具本《法律意见书》，本所特作如下声明： （一）本所依据我国法律 ...

Company Overview - Zhuzhou Qianjin Pharmaceutical Co., Ltd. primarily engages in the research, production, and sales of chemical synthetic raw materials and solid preparations, with key products including Valsartan capsules and other medications [3][5] - Qianjin Xiangjiang Pharmaceutical's nine centralized procurement varieties have seen sales growth exceeding 20% year-on-year, while Qianjin Xieli Pharmaceutical's product, Benazepril, has experienced over 30% sales growth [3][5] Revenue Analysis - The company has reported significant revenue from centralized procurement, with the revenue from centralized procurement increasing substantially over the reporting period [9][10] - For Qianjin Xiangjiang Pharmaceutical, the revenue from centralized procurement accounted for 57.09% in 2024, up from 7.50% in 2020, indicating a strong shift towards centralized procurement sales [9][10] - The average selling price for centralized procurement has decreased from 7.66 to 6.61, while the non-centralized procurement price has also seen a decline from 25.99 to 17.50 [9][10] Market Position and Competitive Landscape - The market for hypertension medications is projected to grow, with the number of hypertension patients in China expected to reach 400 million by 2030, driving demand for products like Valsartan [7][8] - Qianjin Xiangjiang holds approximately 3% market share in the Valsartan segment, while its market share in other products varies, indicating a competitive landscape with several key players [7][8] - The company benefits from a self-operated team and strong brand recognition, which enhances its market position against competitors [7][8] Product Development and Pipeline - The company has several products undergoing research and development, with a focus on expanding its portfolio in response to market needs [6][8] - The market for liver protection drugs, such as Silymarin, is expected to grow significantly, with Qianjin Xieli's market share projected to reach 40% by 2030 [8] Cost and Expense Management - The company has optimized its production processes, which is expected to enhance its cost management and pricing strategies in future centralized procurement rounds [8][9] - The gross profit margin for centralized procurement products has improved, reflecting better cost control and pricing strategies [9][10]

关于株洲千金药业股份有限公司 发行股份及支付现金购买资产暨关联交易 申请的审核问询函 独立财务顾问 签署日期：二〇二五年七月 6-1-1 上海证券交易所： 按照贵所下发的《关于株洲千金药业股份有限公司发行股份及支付现金购买 资产暨关联交易申请的审核问询函》(上证上审(并购重组)(2025)23 号)(以下简 称"审核问询函")的要求，株洲千金药业股份有限公司(以下简称"公司"、 "上市公司"或"千金药业")及相关中介机构就审核问询函所提问题进行了认 真讨论分析，并按照要求在《株洲千金药业股份有限公司发行股份及支付现金购 买资产并募集配套资金暨关联交易报告书(草案)(修订稿)》(以下简称"重组报 告书")中进行了补充披露，现将相关回复说明如下。 本审核问询函回复（以下简称"本回复"）中的报告期指 2022 年、2023 年、 2024 年；除此之外，如无特别说明，本回复所述的词语或简称与重组报告书中 "释义"所定义的词语或简称具有相关的含义。在本回复中，若合计数与各分项 数值相加之和在尾数上存在差异，均为四舍五入所致。 | 审核问询函所列问题 | 黑体(加粗) | | --- | --- | | 审核问询函所列 ...